<?xml version="1.0" encoding="UTF-8"?><!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.1d3 20150301//EN"  "JATS-archivearticle1.dtd"><article article-type="research-article" dtd-version="1.1d3" xmlns:xlink="http://www.w3.org/1999/xlink"><front><journal-meta><journal-id journal-id-type="nlm-ta">elife</journal-id><journal-id journal-id-type="hwp">eLife</journal-id><journal-id journal-id-type="publisher-id">eLife</journal-id><journal-title-group><journal-title>eLife</journal-title></journal-title-group><issn publication-format="electronic">2050-084X</issn><publisher><publisher-name>eLife Sciences Publications, Ltd</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="publisher-id">26109</article-id><article-id pub-id-type="doi">10.7554/eLife.26109</article-id><article-categories><subj-group subj-group-type="display-channel"><subject>Research Article</subject></subj-group><subj-group subj-group-type="heading"><subject>Biochemistry and Chemical Biology</subject></subj-group><subj-group subj-group-type="heading"><subject>Cell Biology</subject></subj-group></article-categories><title-group><article-title>PPP1R15A-mediated dephosphorylation of eIF2α is unaffected by Sephin1 or Guanabenz</article-title></title-group><contrib-group><contrib contrib-type="author" corresp="yes" id="author-19681"><name><surname>Crespillo-Casado</surname><given-names>Ana</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="corresp" rid="cor1">*</xref><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-19674"><name><surname>Chambers</surname><given-names>Joseph E</given-names></name><contrib-id contrib-id-type="orcid">http://orcid.org/0000-0003-4675-0053</contrib-id><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-81734"><name><surname>Fischer</surname><given-names>Peter M</given-names></name><xref ref-type="aff" rid="aff2">2</xref><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-19045"><name><surname>Marciniak</surname><given-names>Stefan J</given-names></name><contrib-id contrib-id-type="orcid">http://orcid.org/0000-0001-8472-7183</contrib-id><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" corresp="yes" id="author-1174"><name><surname>Ron</surname><given-names>David</given-names></name><contrib-id contrib-id-type="orcid">http://orcid.org/0000-0002-3014-5636</contrib-id><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="corresp" rid="cor2">*</xref><xref ref-type="other" rid="par-1"/><xref ref-type="other" rid="par-2"/><xref ref-type="fn" rid="conf1"/></contrib><aff id="aff1"><institution content-type="dept">Cambridge Institute for Medical Research</institution>, <institution>University of Cambridge</institution>, <addr-line><named-content content-type="city">Cambridge</named-content></addr-line>, <country>United Kingdom</country></aff><aff id="aff2"><institution content-type="dept">Division of Biomolecular Science and Medicinal Chemistry, School of Pharmacy</institution>, <institution>University of Nottingham</institution>, <addr-line><named-content content-type="city">Nottingham</named-content></addr-line>, <country>United Kingdom</country></aff></contrib-group><contrib-group content-type="section"><contrib contrib-type="editor" id="author-1133"><name><surname>Malhotra</surname><given-names>Vivek</given-names></name><role>Reviewing editor</role><aff><institution>The Barcelona Institute of Science and Technology</institution>, <country>Spain</country></aff></contrib></contrib-group><author-notes><corresp id="cor1"><label>*</label>For correspondence: <email>ac880@cam.ac.uk</email> (AC);</corresp><corresp id="cor2"><label>*</label>For correspondence: <email>dr360@medschl.cam.ac.uk</email> (DR);</corresp></author-notes><pub-date date-type="pub" publication-format="electronic"><day>27</day><month>04</month><year>2017</year></pub-date><volume>6</volume><elocation-id>e26109</elocation-id><history><date date-type="received"><day>16</day><month>02</month><year>2017</year></date><date date-type="accepted"><day>21</day><month>04</month><year>2017</year></date></history><permissions><copyright-statement>© 2017, Crespillo-Casado et al</copyright-statement><copyright-year>2017</copyright-year><copyright-holder>Crespillo-Casado et al</copyright-holder><license xlink:href="http://creativecommons.org/licenses/by/4.0/"><license-p>This article is distributed under the terms of the <ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/4.0/">Creative Commons Attribution License</ext-link> permitting unrestricted use and redistribution provided that the original author and source are credited.</license-p></license></permissions><self-uri content-type="pdf" xlink:href="elife-26109-v1.pdf"/><abstract><p>Dephosphorylation of translation initiation factor 2 (eIF2α) terminates signalling in the mammalian integrated stress response (ISR) and has emerged as a promising target for modifying the course of protein misfolding diseases. The [(<italic>o</italic>-chlorobenzylidene)amino]guanidines (Guanabenz and Sephin1) have been proposed to exert protective effects against misfolding by interfering with eIF2α-P dephosphorylation through selective disruption of a PP1-PPP1R15A holophosphatase complex. Surprisingly, they proved inert in vitro affecting neither stability of the PP1-PPP1R15A complex nor substrate-specific dephosphorylation. Furthermore, eIF2α-P dephosphorylation, assessed by a kinase shut-off experiment, progressed normally in Sephin1-treated cells. Consistent with its role in defending proteostasis, Sephin1 attenuated the IRE1 branch of the endoplasmic reticulum unfolded protein response. However, repression was noted in both wildtype and <italic>Ppp1r15a</italic> deleted cells and in cells rendered ISR-deficient by CRISPR editing of the <italic>Eif2s1</italic> locus to encode a non-phosphorylatable eIF2α (eIF2α<italic><sup>S51A</sup></italic>). These findings challenge the view that [(o-chlorobenzylidene)amino]guanidines restore proteostasis by interfering with eIF2α-P dephosphorylation.</p></abstract><kwd-group kwd-group-type="research-organism"><title>Research organism</title><kwd>Human</kwd><kwd>Other</kwd></kwd-group><funding-group><award-group id="par-1"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/100010269</institution-id><institution>Wellcome</institution></institution-wrap></funding-source><award-id>200848/Z/16/Z</award-id><principal-award-recipient><name><surname>Ron</surname><given-names>David</given-names></name></principal-award-recipient></award-group><award-group id="par-2"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/100010269</institution-id><institution>Wellcome</institution></institution-wrap></funding-source><award-id>100140</award-id><principal-award-recipient><name><surname>Ron</surname><given-names>David</given-names></name></principal-award-recipient></award-group><funding-statement>The funders had no role in study design, data collection and interpretation, or the decision to submit the work for publication.</funding-statement></funding-group></article-meta></front><back><sec id="s1" sec-type="additional-information"><title>Additional information</title><fn-group content-type="competing-interest"><title>Competing interest</title><fn fn-type="conflict" id="conf1"><p>The authors declare that no competing interests exist.</p></fn></fn-group></sec><sec sec-type="supplementary-material"><supplementary-material><ext-link xlink:href="elife-26109-supp-v1.zip">Download zip</ext-link><p>Any figures and tables for this article are included in the PDF. The zip folder contains additional supplemental files.</p></supplementary-material></sec></back></article>